Table 2.

Examples of available PD-L1 detection and therapeutic antibodies

Therapeutic agentCompanyCompanion PD-L1 detection antibodyExamples of trials by histologyComments
Anti-PD-1
 NivolumabBMS28-8Melanoma, NSCLC, RCC, Hodgkin's lymphoma, other solid tumorsFDA (USA) approved for refractory unresectable/advanced melanoma (12/22/14); approved in Japan for unresectable melanoma (7/4/14)
 Pembrolizumab (MK-3475, lambrolizumab)MerckMerck PD-L1 IHC assayNSCLC, other solid tumorsFDA (USA) approved for ipilimumab-refractory melanoma (9/4/14)
 Pidilizumab (CT-011)CuretechNHL, melanoma, RCC
 AMP-224, AMP-514AmplimmunePhase 1
 “Anti-PD-1”Novartis/CoStimPhase 1
Anti-PD-L1
 BMS-946559BMS28-8
 MPDL3280AGenentech/RocheRoche PD-L1 IHC assayNSCLC, melanoma, RCC
 MEDI4736MedImmune/AstrazenecaSP263 Ventana IHCNSCLC, other solid tumors
 MSB0010718CEMD Serono (Merck)Phase 1

Abbreviations: BMS, Bristol-Myers Squibb; NHL, non-Hodgkin lymphoma.